EMA Adopts a New Pharmaceutical Form of Selumetinib By Ogkologos - December 16, 2025 364 0 Facebook Twitter Google+ Pinterest WhatsApp It is associated with an extension to the existing indication Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Complete Cancer Prevalence in Europe in 2020 Reveals an Increased Proportion... February 1, 2024 FDA Approves Pembrolizumab for Advanced MSI-H/dMMR Endometrial Carcinoma April 5, 2022 The European Parliament’s Reports Include Several ESMO Asks and Materially Strengthen... July 15, 2026 EMA Recommends Extension of Therapeutic Indications for Olaparib June 27, 2022 Load more HOT NEWS Program Helps Medically Underserved, Minority Cancer Survivors Be More Active ESMO Announces Winners of its Awards 2020 [ESMO Press Release] Learning to Live With Cancer: A Survivor’s Story New on NCI’s Websites for November 2024
